CompletedPhase 3NCT00002561
Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease
Studying Nodular lymphocyte predominant Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NCIC Clinical Trials Group
- Principal Investigator
- Ralph M. Meyer, MD, FRCPCMargaret and Charles Juravinski Cancer Centre
- Intervention
- bleomycin sulfate(biological)
- Enrollment
- 405 target
- Eligibility
- 16 years · All sexes
- Timeline
- 1994 – 2012
Study locations (22)
- Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Cross Cancer Institute, Edmonton, Alberta, Canada
- BCCA - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada
- The Vitalite Health Network - Dr. Leon Richard, Moncton, New Brunswick, Canada
- Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada
- Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada
- QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
- Health Sciences North, Greater Sudbury, Ontario, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
- Trillium Health Partners - Credit Valley Hospital, Mississauga, Ontario, Canada
- Stronach Regional Health Centre at Southlake, Newmarket, Ontario, Canada
- Lakeridge Health Oshawa, Oshawa, Ontario, Canada
- Algoma District Cancer Program, Sault Ste. Marie, Ontario, Canada
- Humber River Hospital, Toronto, Ontario, Canada
- Sinai Health System, Toronto, Ontario, Canada
- +7 more locations on ClinicalTrials.gov
Collaborators
Eastern Cooperative Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002561 on ClinicalTrials.govOther trials for Nodular lymphocyte predominant Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06098430Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)St. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialNational Cancer Institute (NCI)
See all trials for Nodular lymphocyte predominant Hodgkin lymphoma →